Analysis of ctDNA Pinpoints Responders to Second-Line GIST Therapy

(MedPage Today) -- Circulating tumor DNA (ctDNA) analysis of KIT mutational status may be able to guide second-line treatment in patients with imatinib-resistant gastrointestinal stromal tumors (GIST), according to an exploratory analysis from...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news